×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:RDUS

Radius Health Stock Forecast, Price & News

$10.48
+0.11 (+1.06%)
(As of 07/1/2022 03:59 PM ET)
Add
Compare
Today's Range
$10.24
$10.49
50-Day Range
$5.53
$10.84
52-Week Range
$4.97
$23.00
Volume
50,580 shs
Average Volume
1.98 million shs
Market Capitalization
$498.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.60

Radius Health MarketRank™ Forecast

Analyst Rating
Hold
1.80 Rating Score
Upside/​Downside
17.9% Downside
$8.60 Price Target
Short Interest
Bearish
17.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.53
Upright™ Environmental Score
News Sentiment
0.57mentions of Radius Health in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$2.66 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.18) to $0.38 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.30 out of 5 stars

Medical Sector

1051st out of 1,428 stocks

Pharmaceutical Preparations Industry

513th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive RDUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

Radius Health logo

About Radius Health (NASDAQ:RDUS) Stock

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

RDUS Stock News Headlines

Short Volatility Alert: Radius Health, Inc.
Radius Health (NASDAQ:RDUS) Price Target Raised to $10.00
Radius Health (NASDAQ:RDUS) Sees Large Volume Increase
4 Analysts Have This to Say About Radius Health
Radius Health jumps 14% on $890M buyout offer
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDUS
Employees
293
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
7/04/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$8.60
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
-17.9%
Consensus Rating
Hold
Rating Score (0-4)
1.8
Research Coverage
5 Analysts

Profitability

Net Income
$-70,180,000.00
Pretax Margin
-33.52%

Debt

Sales & Book Value

Annual Sales
$229.97 million
Book Value
($5.33) per share

Miscellaneous

Free Float
46,777,000
Market Cap
$498.85 million
Optionable
Optionable
Beta
0.55














Radius Health Frequently Asked Questions

Should I buy or sell Radius Health stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Radius Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View analyst ratings for Radius Health
or view top-rated stocks.

What is Radius Health's stock price forecast for 2022?

5 analysts have issued 12-month price objectives for Radius Health's shares. Their RDUS stock forecasts range from $7.00 to $10.00. On average, they expect Radius Health's stock price to reach $8.60 in the next year. This suggests that the stock has a possible downside of 17.9%.
View analysts' price targets for Radius Health
or view top-rated stocks among Wall Street analysts.

How has Radius Health's stock price performed in 2022?

Radius Health's stock was trading at $6.92 at the start of the year. Since then, RDUS shares have increased by 51.4% and is now trading at $10.48.
View the best growth stocks for 2022 here
.

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Radius Health
.

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) released its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.18. The biopharmaceutical company earned $43.16 million during the quarter, compared to analyst estimates of $51.42 million. During the same quarter in the prior year, the firm posted ($0.34) EPS.
View Radius Health's earnings history
.

Who are Radius Health's key executives?

Radius Health's management team includes the following people:
  • Mr. G. Kelly Martin, CEO, Pres & Director (Age 63, Pay $600.48k)
  • Ms. Danielle Holtschlag, VP of Sales & Head of U.S. Sales Channels (Age 44, Pay $299.3k)
  • Ms. Chhaya Shah, Sr. VP & Chief Bus. Officer (Age 58, Pay $631.62k)
  • Dr. Stavros C. Manolagas, Founder & Member of the Scientific Advisory Board
  • Dr. John Thomas Potts Jr., DSc, M.D., Founder & Member of the Scientific Advisory Board (Age 90)
  • Dr. Michael Rosenblatt M.D., Founder, Board Observer & Member of Scientific Advisory Board (Age 74)
  • Dr. John A. Katzenellenbogen, Founder & Member of the Scientific Advisory Board
  • Mr. Mark William Conley CPA, VP, CFO, Principal Accounting Officer & Treasurer (Age 60)
  • Mr. Peter A. Schwartzman, Head of Corp. Fin.
  • Ethan Holdaway, Head of Investor Relations

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $10.48.

How much money does Radius Health make?

Radius Health (NASDAQ:RDUS) has a market capitalization of $498.85 million and generates $229.97 million in revenue each year. The biopharmaceutical company earns $-70,180,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

How many employees does Radius Health have?

Radius Health employs 293 workers across the globe.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The official website for Radius Health is www.radiuspharm.com. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at bryan@radiuspharm.com, or via fax at 617-551-4701.

This page (NASDAQ:RDUS) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.